851440-19-2

Basic information

• Product Name: (Intermediates of Rosuvastatin Calcium R-4
• Synonyms: (Intermediates of Rosuvastatin Calcium R-4
• CAS NO: 851440-19-2
• Molecular Weight: 535.637
• Mol File: 851440-19-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (Intermediates of Rosuvastatin Calcium R-4(CAS DataBase Reference)
• NIST Chemistry Reference: (Intermediates of Rosuvastatin Calcium R-4(851440-19-2)
• EPA Substance Registry System: (Intermediates of Rosuvastatin Calcium R-4(851440-19-2)

Safety Data

• Hazardous Substances Data: 851440-19-2(Hazardous Substances Data)

Usage

Description

Intermediates of Rosuvastatin Calcium R-4 are a group of chemicals that play a crucial role in the synthesis of the cholesterol-lowering medication rosuvastatin calcium. These intermediates are essential building blocks in the creation of the final pharmaceutical product, undergoing several chemical transformations and purification steps to ensure the final product meets the required quality and purity standards for use in pharmaceutical formulations.

Uses

Used in Pharmaceutical Industry:
Intermediates of Rosuvastatin Calcium R-4 are used as essential building blocks for the synthesis of rosuvastatin calcium, a widely prescribed medication for the treatment of high cholesterol and related conditions. They undergo precise reactions and purification steps to create the final active ingredient of the medication, ensuring its quality and purity for pharmaceutical formulations.
Used in Cholesterol-Lowering Medications:
Intermediates of Rosuvastatin Calcium R-4 are used as key components in the development of cholesterol-lowering medications, specifically rosuvastatin calcium. They contribute to the overall effectiveness of the medication in reducing high cholesterol levels and managing related health conditions.

Upstream product

• 164576-45-8 (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid methyl ester 
• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 124752-23-4 tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 67-56-1 methanol 
• 140164-51-8 methyl 2-((4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-yl)acetate 
• 171523-71-0 (+)-(3R,5S)-Methyl 6-acetoxy-3,5-(isopropylidenedioxy)hexanoate 
• 1388624-31-4 2-((4R,6S)-2,2-dimethyl-6-((1-methyl-1H-tetrazol-5-ylthio)methyl)-1,3-dioxan-4-yl)acetic acid methyl ester 
• 1388624-32-5 2-((4R,6S)-6-((1-methyl-1H-tetrazol-5-ylsulfonyl)methyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate methyl ester 
• 147118-37-4 N-[4-(4-fluorophenyl)-5-formyl-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide 
• 391218-16-9 2-((4R,6S)-6-(chloromethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid methyl ester 
• 77-76-9 2,2-dimethoxy-propane 
• 1388627-65-3 2-((4R,6S)-6-((benzo[d]thiazol-2-ylsulfonyl)methyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic acid methyl ester 
• 67-64-1 acetone 
• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 

Downstream Products

• 918544-87-3 (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxy-N-methylhept-6-enamide 
• 503610-43-3 Rosuvastatin lactone 
• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 917805-79-9 rosuvastatin tetramethyl ammonium salt 
• 917805-74-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid-2-methylpropan-2-amine 

Relevant articles and documents

Synthesis of rosuvastatin intermediate synthesis process

The present invention discloses a synthesis process of (4R,6S,E)-2-{6-[2-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl (methylsulfonyl) amino) pyrimidin-5-yl] ethenyl]-2,2-dimethyl-1,3-epoxyhexane-4-yl} acetate alkyl ester. With an aprotic polar solvent as solvent, 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonyl amino)-5-pyrimidine methyl, n-butyl lithium, 2,2,6,6-tetramethyl piperidine or LDA react with trimethyl silicon chloride; and then the reaction products react with (4R-cis)-6-[(acetyloxy) methyl]-2,2-dimethyl-1,3-dioxo hexane-4-alkyl acetate under catalysis of cesium fluoride in an aprotic polar solvent to produce the target product. The process uses trimethyl silicon as a condensation agent, and does not use alkali; the cesium fluoride is directly used as a catalyst; and the usage amount and three wastes are less. Z type condensation ethylenic bond is less than 10%, which is much less than the triphenylphosphine process. The reaction process does not need low temperature, is easy to realize industrialization and has the advantages of easily available raw materials and low cost.

Synthetic method of rosuvastatin

The invention provides a synthetic method of rosuvastatin. The method is characterized in that butyl rosuvastatin is esterified in the presence of a neutral titanate catalyst to prepare methyl rosuvastatin. The method has the advantages of low cost and high yield, and provides a new valued approach for synthesis of the methyl rosuvastatin.

Synthetic studies on statins. Part 3: A facile synthesis of rosuvastatin calcium through catalytic enantioselective allylation strategy

A concise and stereocontrolled synthesis of rosuvastatin calcium has been accomplished, with the key steps including a Keck enantioselective allylation of chloroacetaldehyde with allyltributylstannane to install 5R-stereocenter and a VO(acac)2-catalyzed syn-diastereoselective epoxidation of (S)-1-chloropent-4-en-2-ol to set the requisite 3R-chirality.